FDA Issues New Guidance on AI in Drug Development, Emphasizing Risks and Early Engagement

January 7, 2025 - 16:44

The FDA has released new guidance addressing the use of artificial intelligence (AI) in drug development, emphasizing the potential risks associated with this rapidly evolving technology. The agency warns that improper use of AI could lead to life-threatening consequences, underscoring the critical need for early engagement between sponsors and regulators.

In the guidance, the FDA calls for sponsors to provide comprehensive information about the development and maintenance of AI models. This includes detailed documentation of the algorithms used, data sources, and validation processes. By ensuring transparency and thorough communication, the FDA aims to mitigate risks and enhance the safety and efficacy of AI-driven drug development.

The agency's proactive stance reflects a growing recognition of the complexities and challenges posed by AI technologies in healthcare. As AI continues to play an increasingly prominent role in the pharmaceutical industry, the FDA's guidance serves as a crucial framework for navigating its potential pitfalls while fostering innovation.